Quarterly ResultNov 3, 2026, 08:06 AM
IDEAYA Biosciences Q3 2026 Net Loss $125.7M; NDA Filed for Darovasertib
AI Summary
IDEAYA Biosciences reported its third quarter 2026 financial results, with $1.15 billion in cash and equivalents. The company announced the completion of its NDA submission for darovasertib plus crizotinib in metastatic uveal melanoma and presented updated data for IDE849 in SCLC and NEC. R&D expenses increased to $121.6 million, contributing to a net loss of $125.7 million for the quarter. The company also announced the closure of the Phase 3 OptimUM-010 trial, expecting cost savings to be reallocated to other programs.
Key Highlights
- IDEAYA reported $1.15 billion in cash, cash equivalents, and marketable securities as of September 30, 2026.
- Collaboration revenue for Q3 2026 was $10.2 million, up from $8.9 million in Q2 2026.
- R&D expenses for Q3 2026 were $121.6 million, an increase from $108.7 million in Q2 2026.
- G&A expenses for Q3 2026 were $26.3 million, up from $22.5 million in Q2 2026.
- Net loss for Q3 2026 was $125.7 million, compared to a net loss of $112.5 million in Q2 2026.
- Completed NDA submission for darovasertib plus crizotinib in metastatic uveal melanoma.
- Updated data for IDE849 (DLL3 TOP1 ADC) in relapsed SCLC and NEC presented at ESMO 2026.
- IDEAYA R&D Day scheduled for November 16th to highlight preclinical data on MTAP/CDKN2A deficiency.
Price Impact
More from IDYA